Triflusal (BioDeep_00000184524)

   

human metabolite blood metabolite


代谢物信息卡片


2-(acetyloxy)-4-(trifluoromethyl)benzoic acid

化学式: C10H7F3O4 (248.0296)
中文名称: 三氟醋柳酸
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O
InChI: InChI=1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)

描述信息

B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors

同义名列表

4 个代谢物同义名

2-(acetyloxy)-4-(trifluoromethyl)benzoic acid; 2-Acetoxy-4-trifluoromethylbenzoic acid; Triflusal; Disgren



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Sung Min Park, Joomi Lee, Sook Jin Seong, Jong Gwang Park, Mi-Ri Gwon, Mi-sun Lim, Hae Won Lee, Young-Ran Yoon, Dong Heon Yang, Kwang-Il Kwon, Seunghoon Han. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. BMC pharmacology & toxicology. 2014 Dec; 15(?):75. doi: 10.1186/2050-6511-15-75. [PMID: 25534747]
  • Hwi-yeol Yun, Wonku Kang, Byung-yo Lee, Sunkyung Park, Young-Ran Yoon, Jin Yeul Ma, Kwang-il Kwon. Semi-mechanistic modelling and simulation of inhibition of platelet aggregation by antiplatelet agents. Basic & clinical pharmacology & toxicology. 2014 Oct; 115(4):352-9. doi: 10.1111/bcpt.12222. [PMID: 24612881]
  • M Wang, Q Zhang, M Huang, S Zong, W Hua, W Zhou. Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Drug research. 2014 May; 64(5):263-8. doi: 10.1055/s-0033-1357180. [PMID: 24105106]
  • Hae Won Lee, Mi-sun Lim, Sook Jin Seong, Joomi Lee, Jeonghyeon Park, Jeong Ju Seo, Hwi-yeol Yun, In-hwan Baek, Kwang-il Kwon, Young-Ran Yoon. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Expert opinion on drug metabolism & toxicology. 2011 Dec; 7(12):1471-9. doi: 10.1517/17425255.2011.630661. [PMID: 22098139]
  • Carlos R Cámara-Lemarroy, Francisco J Guzmán-de la Garza, Paula Cordero-Pérez, Gabriela Alarcón-Galván, Liliana Torres-Gonzalez, Linda E Muñoz-Espinosa, Nancy E Fernández-Garza. Comparative effects of triflusal, S-adenosylmethionine, and dextromethorphan over intestinal ischemia/reperfusion injury. TheScientificWorldJournal. 2011; 11(?):1886-92. doi: 10.1100/2011/583603. [PMID: 22125445]
  • Iñaki Izquierdo, Javier Borja, Sandra Rovira, Pilar Pelagio, Ferran Torres, Jesus Cebrecos, Julián García-Rafanell. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study. Arzneimittel-Forschung. 2010; 60(1):36-41. doi: 10.1055/s-0031-1296246. [PMID: 20184225]
  • Sara Montanaro, Virginie Lhiaubet-Vallet, M Consuelo Jiménez, Miguel Blanca, Miguel Angel Miranda. Photonucleophilic addition of the epsilon-amino group of lysine to a triflusal metabolite as a mechanistic key to photoallergy mediated by the parent drug. ChemMedChem. 2009 Jul; 4(7):1196-202. doi: 10.1002/cmdc.200900066. [PMID: 19462393]
  • Maria Montero Domínguez, Berta González, Jens Zimmer. Neuroprotective effects of the anti-inflammatory compound triflusal on ischemia-like neurodegeneration in mouse hippocampal slice cultures occur independent of microglia. Experimental neurology. 2009 Jul; 218(1):11-23. doi: 10.1016/j.expneurol.2009.03.023. [PMID: 19341733]
  • José-Manuel Fernández-Real, Abel López-Bermejo, Ana-Belén Ropero, Sandra Piquer, Angel Nadal, Judit Bassols, Roser Casamitjana, Ramón Gomis, Eva Arnaiz, Iñaki Pérez, Wifredo Ricart. Salicylates increase insulin secretion in healthy obese subjects. The Journal of clinical endocrinology and metabolism. 2008 Jul; 93(7):2523-30. doi: 10.1210/jc.2007-1212. [PMID: 18460568]
  • Emilio García Quetglas, Miguel Angel Campanero, Belén Sádaba, Manuel Escolar, Jose Ramón Azanza. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. Arzneimittel-Forschung. 2008; 58(6):283-7. doi: 10.1055/s-0031-1296508. [PMID: 18677970]
  • A Falco, F Salvati, E Vitacolonna, G Avellone, A Pinto, C Di Febbo, E Ballone, M Di Nicola, G Ciabattoni, G Davì. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. Atherosclerosis. 2005 Dec; 183(2):329-35. doi: 10.1016/j.atherosclerosis.2005.03.014. [PMID: 16285996]
  • M Valle, M J Barbanoj, A Donner, I Izquierdo, U Herranz, N Klein, H G Eichler, M Müller, M Brunner. Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. European journal of clinical pharmacology. 2005 Apr; 61(2):103-11. doi: 10.1007/s00228-004-0887-0. [PMID: 15711832]
  • J A González-Correa, M M Arrebola, I M Ureña, D Ruiz-Villafranca, J Muñoz-Marín, A Guerrero, F Sánchez de la Cuesta, J P De La Cruz. Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids. Naunyn-Schmiedeberg's archives of pharmacology. 2005 Jan; 371(1):81-8. doi: 10.1007/s00210-004-1001-y. [PMID: 15602657]
  • J A González-Correa, M M Arrebola, I M Ureña, A Guerrero, J Muñoz-Marín, D Ruiz-Villafranca, F Sánchez De La Cuesta, J P De La Cruz. Effects of triflusal on oxidative stress, prostaglandin production and nitric oxide pathway in a model of anoxia-reoxygenation in rat brain slices. Brain research. 2004 Jun; 1011(2):148-55. doi: 10.1016/j.brainres.2004.02.069. [PMID: 15157801]
  • Hea-Young Cho, Tae-Jin Jeong, Yong-Bok Lee. Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Dec; 798(2):257-64. doi: 10.1016/j.jchromb.2003.09.049. [PMID: 14643505]
  • F Boscá, M C Cuquerella, M L Marín, M A Miranda. Photochemistry of 2-hydroxy-4-trifluoromethylbenzoic acid, major metabolite of the photosensitizing platelet antiaggregant drug triflusal. Photochemistry and photobiology. 2001 May; 73(5):463-8. doi: 10.1562/0031-8655(2001)0730463pohtam2.0.co2. [PMID: 11367565]
  • F Escamilla, A Espigares, R Hervás, M D Fernández, R Vela, T García. [Fibromuscular dysplasia with moyamoya phenomenon in a patient with Alport's syndrome. A type IV collagen disorder]. Revista de neurologia. 2000 Apr; 30(8):736-40. doi: NULL. [PMID: 10893738]
  • R Mis, J Ramis, L Conte, J Forn. In-vitro protein binding interaction between a metabolite of triflusal, 2-hydroxy-4-trifluoromethylbenzoic acid and other drugs. The Journal of pharmacy and pharmacology. 1992 Nov; 44(11):935-7. doi: 10.1111/j.2042-7158.1992.tb03241.x. [PMID: 1361542]
  • R Mis, J Ramis, L Conte, J Forn. Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man. European journal of clinical pharmacology. 1992; 42(2):175-9. doi: 10.1007/bf00278480. [PMID: 1618249]
  • J Ramis, R Mis, J Forn. Pharmacokinetics of triflusal and its main metabolite in rats and dogs. European journal of drug metabolism and pharmacokinetics. 1991 Oct; 16(4):261-8. doi: 10.1007/bf03189970. [PMID: 1823869]
  • J Ramis, R Mis, J Forn, J Torrent, E Gorina, F Jané. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. European journal of drug metabolism and pharmacokinetics. 1991 Oct; 16(4):269-73. doi: 10.1007/bf03189971. [PMID: 1823870]
  • E Esmatjes, J I Conget, J Gaya, M R Fernandez, J P Ferrer, F Rivera, E Vilardell. Effects of thromboxane synthesis inhibitor triflusal on renal hemodynamics in microalbuminuric diabetic patients. Diabetes care. 1990 Nov; 13(11):1114-7. doi: 10.2337/diacare.13.11.1114. [PMID: 2261825]
  • J Ramis, J Torrent, R Mis, L Conte, M J Barbanoj, J Jané, J Forn. Pharmacokinetics of triflusal after single and repeated doses in man. International journal of clinical pharmacology, therapy, and toxicology. 1990 Aug; 28(8):344-9. doi: NULL. [PMID: 2272716]
  • J P de la Cruz, J Pavia, I Bellido, M C González, F Sánchez de la Cuesta. Platelet antiaggregatory effect of triflusal in human whole blood. Methods and findings in experimental and clinical pharmacology. 1988 Apr; 10(4):273-7. doi: NULL. [PMID: 3386335]
  • J P De la Cruz, J Pavia, J Garcia-Arnes, F Sanchez de la Cuesta. Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. European journal of haematology. 1988 Mar; 40(3):232-6. doi: 10.1111/j.1600-0609.1988.tb00829.x. [PMID: 2965654]
  • M J Dominguez, M Vacas, Y Sáez, I Olabarría, A Velasco, J A Iriarte, J Forn. Effects of triflusal in patients with prosthetic heart valves. Clinical therapeutics. 1985; 7(3):357-60. doi: NULL. [PMID: 3838919]